Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,001 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).
Lebellec L, Bertucci F, Tresch-Bruneel E, Bompas E, Toiron Y, Camoin L, Mir O, Laurence V, Clisant S, Decoupigny E, Blay JY, Goncalves A, Penel N. Lebellec L, et al. Among authors: blay jy. Oncotarget. 2016 Nov 8;7(45):73984-73994. doi: 10.18632/oncotarget.12172. Oncotarget. 2016. PMID: 27659533 Free PMC article.
Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, Adenis A, Viens P, Rios M, Bompas E, Cupissol D, Guillemet C, Kerbrat P, Fayette J, Chabaud S, Berthaud P, Perol D. Blay JY, et al. J Clin Oncol. 2007 Mar 20;25(9):1107-13. doi: 10.1200/JCO.2006.09.0183. J Clin Oncol. 2007. PMID: 17369574 Clinical Trial.
Imatinib as a possible cause of severe rhabdomyolysis.
Penel N, Blay JY, Adenis A. Penel N, et al. Among authors: blay jy. N Engl J Med. 2008 Jun 19;358(25):2746-7. doi: 10.1056/NEJMc0708896. N Engl J Med. 2008. PMID: 18565874 No abstract available.
Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.
Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY. Penel N, et al. Among authors: blay jy. J Clin Oncol. 2008 Nov 10;26(32):5269-74. doi: 10.1200/JCO.2008.17.3146. Epub 2008 Sep 22. J Clin Oncol. 2008. PMID: 18809609 Clinical Trial.
Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma.
Fayette J, Penel N, Chevreau C, Blay JY, Cupissol D, Thyss A, Guillemet C, Rios M, Rolland F, Fargeot P, Bay JO, Mathoulin-Pelissier S, Coindre JM, Bui-Nguyen B. Fayette J, et al. Among authors: blay jy. Invest New Drugs. 2009 Oct;27(5):482-9. doi: 10.1007/s10637-008-9217-1. Epub 2009 Jan 16. Invest New Drugs. 2009. PMID: 19148579 Clinical Trial.
Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis.
Dufresne A, Bertucci F, Penel N, Le Cesne A, Bui B, Tubiana-Hulin M, Ray-Coquard I, Cupissol D, Chevreau C, Perol D, Goncalves A, Jimenez M, Bringuier PP, Blay JY. Dufresne A, et al. Among authors: blay jy. Br J Cancer. 2010 Aug 10;103(4):482-5. doi: 10.1038/sj.bjc.6605783. Epub 2010 Jul 27. Br J Cancer. 2010. PMID: 20664593 Free PMC article. Clinical Trial.
Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.
Le Cesne A, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, Duffaud F, Chevreau C, Cupissol D, Cioffi A, Emile JF, Chabaud S, Pérol D, Blay JY; French Sarcoma Group. Le Cesne A, et al. Among authors: blay jy. Lancet Oncol. 2010 Oct;11(10):942-9. doi: 10.1016/S1470-2045(10)70222-9. Epub 2010 Sep 21. Lancet Oncol. 2010. PMID: 20864406 Clinical Trial.
1,001 results